Implementation-effectiveness trial of systematic family health history based risk assessment and impact on clinical disease prevention and surveillance activities

Table 3 Participant-Provider discussions

Recommendationa	Participants reporting discussion of relevant topic N (%, 95% CI)b	Participants with relevant CDS recommendation N (%, 95% CI)c	Participants without relevant CDS recommendation N (%)d	P-value
Breast MRI	161 (14.7, 12.7–16.9)	13 (38.2, 22.7 – 56.4)	148 (13.9, 11.9 – 16.2)	< 0.001
Chemoprevention	147 (13.4, 11.5—15.6)	18 (30.5, 19.5 – 40.0)	129 (12.4, 10.5 – 14.6)	< 0.001
Colonoscopy	156 (14.2, 12.2- 16.5)	21 (26.3, 17.3 -37.5)	135 (13.3, 11.3 – 15.6)	0.004
Genetic counselling overall	44 (4.0, 3.0—5.4)	27 (8.7, 5.9 – 12.5)	17 (2.2, 1.3 – 3.5)	< 0.001
GC for breast cancer risk	176 (16.0, 13.9, 18.4)	36 (24.8, 18.2 – 32.8)	140 (14.7, 12.5 – 17.2)	0.003
GC for colon cancer risk	192 (17.5, 15.3—19.9)	32 (28.6, 20.6 – 38.0)	160 (16.2, 14.0 – 18.7)	0.002

^aDiscussion topics relevant for each recommendation as follows: breast MRI (discussion of breast MRI, overall breast cancer [BC] risk), chemoprevention (discussion of chemoprevention, overall BC risk), colonoscopy (discussion of overall colon cancer risk), GC (discussion of GC), GC for BC risk (discussion of GC, overall BC risk), GC for colon cancer risk (discussion of GC, overall colon cancer risk)
^b% of total participants who responded to the survey (1097)
^c% of all participants who responded to the survey and had the specified CDS recommendation
^d% of all participants who responded to the survey and did not have the specified CDS recommendation

ISSN: 1472-6963